Metraipolis › archive › dc_28b2fd77bd98
5-MeO-MiPT — Wikipedia (en)
- Source
- Wikipedia (en)
- Original
- https://en.wikipedia.org/wiki/5-MeO-MiPT
- License (as archived)
- CC-BY-SA-4.0
- Archived
- 2026-11-06T17:32:51.453Z
- SHA-256 of the archived text
667ad2fc1de4fd76d6a072ef8053e6f15b48498400116c5552a9b44e6b46d1f4- Stable URL of this page
https://metraipolis.com/documento/dc_28b2fd77bd98
How to cite
5-MeO-MiPT — Wikipedia (en) — Wikipedia (en), https://en.wikipedia.org/wiki/5-MeO-MiPT (CC-BY-SA-4.0); archived copy: https://metraipolis.com/documento/dc_28b2fd77bd98 (Metraipolis archive dc_28b2fd77bd98, sha256 667ad2fc1de4fd76d6a072ef8053e6f15b48498400116c5552a9b44e6b46d1f4)
BibTeX
@misc{dc28b2fd77bd98,
title = {5-MeO-MiPT — Wikipedia (en)},
howpublished = {Wikipedia (en)},
url = {https://en.wikipedia.org/wiki/5-MeO-MiPT},
note = {License CC-BY-SA-4.0; archived copy https://metraipolis.com/documento/dc_28b2fd77bd98; sha256 667ad2fc1de4fd76d6a072ef8053e6f15b48498400116c5552a9b44e6b46d1f4},
year = {2026}
}Archived text
Reproduced under CC-BY-SA-4.0. Attribution: Wikipedia (en), https://en.wikipedia.org/wiki/5-MeO-MiPT. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
5-MeO-MiPT, also known as 5-methoxy-N-methyl-N-isopropyltryptamine or by its nickname Moxy, is an atypical psychedelic drug of the tryptamine and 5-methoxytryptamine families. It has unique and unusual effects compared to other psychedelic tryptamines. At low doses, its effects include stimulation, tactile and sexual enhancement, some MDMA-like entactogenic effects, and introspective and mild perceptual changes with few or no psychedelic visuals or time dilation, whereas at higher doses, it produces 5-MeO-DMT-like classical psychedelic effects. It is usually taken orally or smoked. The drug acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors, among others. It is closely related in chemical structure and effects to 5-MeO-DiPT, and is also related to other tryptamines like 5-MeO-DMT, 4-HO-MiPT, and MiPT. 5-MeO-MiPT was first described in the literature by Alexander Shulgin and David Repke and colleagues in 1985. It was later described by Shulgin in greater detail in his 1997 book TiHKAL (Tryptamines I Have Known and Loved). The drug was encountered as a novel designer drug in 2004. Recreational use of 5-MeO-MiPT is significant but relatively rare. It is often used as a substitute for 5-MeO-DiPT, which has similar effects but became a controlled substance in the United States in 2003. The Drug Enforcement Administration (DEA) proposed banning 5-MeO-MiPT as well in the 2020s, but later withdrew its proposal amid public opposition. 5-MeO-MiPT, under the developmental code name MSD-001, is being developed for the treatment of psychiatric disorders by Mindstate Design Labs and is in phase 1 clinical trials for this purpose as of 2025. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (deposito sistematico; retro-catalogo: tutte le voci di Wikipedia in inglese, in ordine alfabetico). Fonte: Wikipedia in inglese, voce «5-MeO-MiPT» — https://en.wikipedia.org/wiki/5-MeO-MiPT Wikidata Q4412834: «composto chimico» (dati Wikidata in CC0 1.0) — https://www.wikidata.org/wiki/Q4412834 Autori: i contributori di Wikipedia (cronologia: https://en.wikipedia.org/wiki/5-MeO-MiPT?action=history). Licenza: Creative Commons Attribuzione-Condividi allo stesso modo 4.0 (CC BY-SA 4.0) — https://creativecommons.org/licenses/by-sa/4.0/. Il riuso richiede attribuzione e stessa licenza. Estratto dell'introduzione non modificato nel contenuto; revisione 1379863476, consultata il 2026-11-06T17:25:16.516Z tramite l'API ufficiale di Wikipedia. Impronta SHA-256 dell'estratto: 29d4f311ab7d3d2b5e31be5b15f72abe54c14584d793c93fee1078d24839747a